Six malignancies have confirmed causal ties to HPV, according to current evidence: cervical, oropharyngeal (tonsils and base of tongue), anal, vulvar, vaginal, and penile cancer. HPV is a family of more than 200 related viruses that infect skin and mucosal tissue, and roughly 14 of those strains are classified as high-risk because they can drive normal cells toward precancerous changes and, eventually, invasive disease.
This guide explores each of the six HPV-linked cancers in detail, covering which high-risk strains drive them, how common they are in the United States, and what screening options can catch precancers early.
The Link Between HPV and Cancer Starts With Persistent Infection
HPV spreads through skin-to-skin and mucosal contact, most often during sexual activity. Once inside the body, the virus targets epithelial tissue, the thin layer of cells that lines the mouth, throat, genitals, and anus. In most people, the immune system clears the infection within one to two years, often without any symptoms at all.
When clearance fails, a small fraction of high-risk infections persist for years. During that time, viral DNA can integrate into the host cell’s own genome, disrupting normal controls on cell growth. The stepwise progression from persistent infection to precancerous lesions to invasive cancer typically spans a decade or more, which is why screening catches problems long before symptoms appear.
Low-Risk vs. High-Risk Strains
About 200 HPV types fall into two broad categories. Low-risk strains, including HPV-6 and HPV-11, cause genital warts and recurrent respiratory papillomatosis but almost never lead to cancer. High-risk strains, sometimes called oncogenic types, can drive cellular changes that progress to malignancy if left unchecked.
High-Risk HPV Strains Drive the Majority of Cancers
Fourteen HPV types are officially classified as high-risk or probably carcinogenic. Two stand out: HPV-16 and HPV-18 together account for roughly 70 percent of cervical cancers and a large share of the other HPV-related cancers. Knowing which strain is involved matters because it shapes how clinicians interpret screening results and which vaccine formulation offers the broadest protection.
| High-Risk Strain | Primary Cancers Linked | Relative Contribution |
|---|---|---|
| HPV-16 | Cervical, oropharyngeal, anal, vulvar, penile | Most oncogenic type; dominant in oropharyngeal and anal cancers |
| HPV-18 | Cervical, anal, some oropharyngeal | Second-leading cause of cervical adenocarcinoma |
| HPV-31, 33, 45, 52, 58 | Cervical, anal, vulvar, vaginal | Together responsible for a meaningful share of remaining HPV-positive cancers |
| HPV-6, 11 (low-risk) | Genital warts, recurrent respiratory papillomatosis | No established cancer link |
Strain behavior varies by anatomical site. HPV-16 dominates oropharyngeal tumors, while HPV-18 plays a larger role in cervical adenocarcinoma, a subtype that Pap smears alone can miss. That site-by-strain variation is one reason modern cervical screening increasingly combines a Pap test with an HPV DNA test.
Because those high-risk strains behave differently across tissues, identifying exactly which cancers they cause becomes the natural next question.
The Six Cancers Causally Linked to HPV
Researchers have gathered enough evidence to formally classify six malignancies as causally linked to HPV. Each behaves differently, and each affects different groups.
Cervical Cancer
Roughly 99 percent of cervical cancer cases worldwide trace back to HPV, earning it the label of prototypical HPV-related malignancy. Persistent infection with high-risk strains, most often HPV-16 and HPV-18, drives the gradual progression from cervical intraepithelial neoplasia (CIN) to invasive carcinoma. Regular screening with Pap and HPV tests has made cervical cancer one of the most preventable cancers in countries with high screening rates.
Oropharyngeal Cancer
Tumors of the tonsils and base of the tongue now make oropharyngeal cancer the most common HPV-associated malignancy in the United States. HPV accounts for roughly 70 percent of these cases. Men are affected several times more often than women, and the typical patient is diagnosed in their 50s or 60s, decades after the initial exposure.
Anal Cancer
About 91 percent of anal cancers are HPV-associated, with HPV-16 as the dominant strain. Rates have been climbing for decades, particularly among women and men who have receptive anal intercourse and among people living with HIV.
Vulvar and Vaginal Cancers
About 40 percent of vulvar cancers and 70 percent of vaginal cancers involve HPV as a contributing cause. These malignancies are far less common than cervical cancer, but they share the same high-risk strains and similar progression patterns.
Penile Cancer
Roughly half of all penile cancer cases come back positive for high-risk HPV strains on testing. HPV-associated penile cancer tends to behave more responsively to treatment than HPV-negative disease, but prevention still centers on vaccination and early detection of precursor lesions.
Knowing which cancers HPV actually drives makes it possible to estimate how often each one occurs in the population.
| Cancer Type | Share Attributable to HPV | Most Common Strain(s) |
|---|---|---|
| Cervical | ~99% | HPV-16, HPV-18 |
| Oropharyngeal | ~70% (US) | HPV-16 |
| Anal | ~91% | HPV-16 |
| Vulvar | ~40% | HPV-16 |
| Vaginal | ~70% | HPV-16 |
| Penile | ~50% | HPV-16 |
How Common HPV-Related Cancers Are in the United States
CDC data shows that more than 35,000 HPV-attributable cancer cases occur annually in the United States. Oropharyngeal cancer has surpassed cervical cancer as the most common HPV-associated cancer in American surveillance data, a shift driven by both falling cervical cancer rates and rising HPV-positive throat cancer diagnoses in men.
Demographic Patterns and Long Latency
Anal and oropharyngeal cancers disproportionately affect men, while cervical cancer still claims the highest burden among women with limited screening access. The long latency between initial HPV exposure and cancer diagnosis, often 10 to 20 years or more, means someone diagnosed at 55 may have been infected in their late 20s or earlier. That delay complicates prevention messaging but reinforces the value of vaccinating adolescents before they are exposed.
Long lag times between infection and cancer make routine screening the most practical lever for catching disease early.
Prevalence figures are most useful as a calibration tool: they tell you which HPV-related cancers are common enough to warrant attention, not whether any single individual will develop one.
Screening, Early Detection, and Treatment of Precancers
Cervical cancer is the only HPV-associated cancer with a widely recommended population screening program, and that program has prevented millions of deaths since the mid-20th century. Current guidelines from organizations like the American Cancer Society and the U.S. Preventive Services Task Force recommend cervical cancer screening starting at age 25 and continuing through age 65, using either primary HPV testing, co-testing (Pap plus HPV), or Pap testing alone at defined intervals.
No routine screening program exists yet for oropharyngeal, anal, vulvar, vaginal, or penile cancer, though anal cytology is sometimes used in high-risk groups such as people living with HIV. For these cancers, awareness of symptoms (persistent sore throat, difficulty swallowing, unexplained bleeding, visible lesions) and prompt evaluation remain the main tools.
Practical Screening Checklist
- Cervical screening (women 25–65): Follow current Pap and HPV testing guidelines based on your age and prior results.
- Annual dental and medical exams: Ask your clinician to inspect the mouth, throat, and genital area for unusual lesions.
- Symptom monitoring: Report persistent sore throat, hoarseness, difficulty swallowing, or unexplained bleeding to a provider promptly.
- High-risk follow-up: If you are immunocompromised or have a history of anal intercourse, ask whether anal cytology is appropriate.
- Vaccination status check: Confirm whether you completed the HPV vaccine series during the recommended window.
Vaccination and Other Steps That Lower Cancer Risk
The HPV vaccine is the single most powerful tool for preventing HPV-associated cancers. Gardasil 9, the formulation used in the United States today, protects against nine HPV strains: the seven high-risk types most likely to cause cancer (16, 18, 31, 33, 45, 52, 58) plus HPV-6 and HPV-11, which cause genital warts. Cervarix, used in many other countries, covers HPV-16 and HPV-18.
Timing and Catch-Up Vaccination
Vaccination works best when given before any HPV exposure, which is why the CDC recommends routine vaccination at ages 11 or 12 (it can start as early as age 9). Catch-up vaccination is recommended through age 26. For adults aged 27 to 45, the vaccine is not universally recommended but can be considered through shared clinical decision-making, since exposure may not yet have included all vaccine-covered strains.
Even if you were infected with one HPV strain in the past, vaccination can still protect against the other strains you have not yet encountered.
Complementary Prevention
Vaccination is most effective alongside other proven measures. Consistent condom use reduces (but does not eliminate) HPV transmission because the virus can spread through skin not covered by a condom. Smoking cessation matters because tobacco use compounds the cancer risk in people with persistent HPV infection. Staying current with recommended screening catches the precancerous changes that vaccination cannot address in someone already infected.
Your Clear Next Steps
- Check vaccination records: Confirm whether you and your children have completed the HPV vaccine series.
- Schedule screening: If you are 25 or older with a cervix, book a Pap or HPV test according to current guidelines.
- Address symptoms early: Bring persistent throat, oral, or genital changes to a provider without delay.
- Stop smoking: Tobacco dramatically amplifies the cancer risk from persistent HPV infection.
- Talk to a clinician: Ask whether vaccination between ages 27 and 45 makes sense for your situation.
Bottom Line
Six cancers have a confirmed causal link to HPV: cervical, oropharyngeal, anal, vulvar, vaginal, and penile. Most of these cases trace back to a handful of high-risk strains, especially HPV-16. Vaccination before exposure, routine cervical screening, and prompt evaluation of unusual symptoms together eliminate a large share of the risk. Follow the recommendations of an appropriate specialist doctor for your specific situation.
FAQ
What cancers can HPV actually cause?
Six distinct cancer types fall within HPV’s causal range: cervical, oropharyngeal (tonsils and base of tongue), anal, vulvar, vaginal, and penile. Nearly all cervical cancers are HPV-related, and HPV accounts for roughly 70 percent of oropharyngeal cancers in the United States.
Is HPV really linked to cancer, and how strong is the connection?
The link is strong and well established. About 91 percent of anal cancers, 99 percent of cervical cancers, and roughly 70 percent of oropharyngeal cancers test positive for HPV, with high-risk strains driving the progression from infection to invasive disease over many years.
Which types of HPV are most likely to cause cancer?
Fourteen HPV types are classified as high-risk. HPV-16 and HPV-18 are the most oncogenic and together account for the majority of HPV-related cancers, with HPV-31, 33, 45, 52, and 58 contributing meaningful additional cases.
Are HPV-related cancers only a concern for women?
No. Men face a significant burden, especially from HPV-positive oropharyngeal cancer, which is now the most common HPV-associated cancer in American men. Anal and penile cancers also affect men at meaningful rates.
What are the symptoms of HPV-related cancers?
Symptoms vary by site but commonly include a persistent sore throat, hoarseness, difficulty swallowing, unexplained bleeding, visible lesions, or a lump in the neck or genital area. Because early HPV-related changes often produce no symptoms, cervical screening remains essential for eligible women.
Can HPV cancers be prevented with the HPV vaccine?
Yes, for cancers caused by the strains the vaccine covers. Gardasil 9 targets HPV-16, 18, 31, 33, 45, 52, and 58, which together drive the majority of HPV-related cancers. Vaccination works best before any sexual exposure but still offers partial protection in adults who have not yet encountered every covered strain.
